On November 7, 2022 Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic diseases, reported that its Chief Scientific Officer, Daren Ure, PhD, will present data highlighting the poly-indication potential of its lead drug candidate, rencofilstat, at the upcoming 6th Annual Antifibrotic Drug Development Summit, taking place November 9-11, 2022, in Boston, MA (Press release, Hepion Pharmaceuticals, NOV 7, 2022, View Source [SID1234623244]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is data from 15 independent preclinical studies demonstrating the ability of rencofilstat, acting primarily through inhibition of cyclophilin B, to decrease fibrosis and/or the production of collagen leading to fibrosis in preclinical models related to liver, lung, heart, kidney, and skin fibrosis," said Robert Foster, PharmD, PhD, CEO of Hepion. "Thus, as Dr. Ure will highlight in his presentation at AFDD, rencofilstat shows promise as a collagen-targeting therapeutic for multiple fibrotic diseases, potentially providing Hepion with a true ‘pipeline within a product.’"